Germany’s Leading Medical Cannabis Pharmaceutical Company
Cannamedical Pharma GmbH was founded in Germany with a clear purpose: to professionalise medical cannabis supply within a pharmaceutical framework and improve patient access to clinically validated, EU-GMP certified products. Today, Cannamedical is one of Germany’s most established and respected medical cannabis companies, operating at scale across the DACH region and beyond.
European Scale, Pharmaceutical Standards
Our European operations demonstrate what is possible when medical cannabis is treated as a pharmaceutical product:
- 120,000+ patients per month across Europe receive Cannamedical products through their prescribed treatments
- 1,100+ pharmacy partners in Germany, Austria and the Netherlands stock and dispense our products
- 30+ EU-GMP certified cultivators form our international production network, spanning Portugal, Denmark, Colombia, Australia and beyond
- 100+ products in the formulary, spanning flower, extracts and standardised preparations across a broad range of cannabinoid profiles
Presence Across Europe
Cannamedical Pharma GmbH is active in three major European medical cannabis markets:
- Germany: Largest market. Full legal framework following the 2024 CanG reform. Established relationships across prescribing and pharmacy networks.
- Austria: Prescription-based access system. Active dispensing through partner pharmacies.
- Netherlands: Pioneer medical cannabis market. Long-standing operational presence.
Semdor Pharma Group
Cannamedical Pharma GmbH operates as part of the Semdor Pharma Group — a pharmaceutical group with the resources, regulatory expertise and international infrastructure to support market expansion into new geographies. The Group’s backing means that Cannamedical Britannia’s UK entry is not speculative: it is a structured market expansion supported by proven European operations and a robust financial framework.
Why the United Kingdom?
The UK was one of the first countries in the world to legalise medical cannabis for specialist prescription in 2018. With an estimated 40,000+ patients currently accessing prescribed medical cannabis privately, and a growing prescribing network of specialist clinics, the UK represents a significant and underpenetrated market for a pharmaceutical-grade EU-GMP supplier. Cannamedical Britannia’s UK entry in 2026 represents the natural next step in our European expansion strategy.
Explore our quality standards or find out how to partner with us as a clinician.